tumor-infiltrating lymphocytes

  •  

    The Latest in Melanoma Treatment: A Guest Perspective

    With: Ryan Sullivan, MD

    What’s new in melanoma treatment? Our chief scientist Emma Shtivelman, PhD, recently outlined the latest options. Here, our Curious Dr. George invites a response from Ryan Sullivan, MD, Associate Director of the Melanoma Program at Massachusetts General Hospital Cancer Center and Associate Professor at Harvard Medical School. Curious Dr. George: As a melanoma expert, what are your thoughts on the treatments outlined in our… Read more »

  •  

    Predicting If an Immune Checkpoint Drug Will Work

    Emma Shtivelman, PhD

    Drugs that activate the immune system to attack cancer in a process known as immune checkpoint blockade (ICB) are a focus of intense investigation. A number of them are already approved by the U.S. Food and Drug Administration (FDA) for various cancers; namely, the anti-CTLA4 antibody ipilimumab (Yervoy), two anti-PD-1 antibodies: pembrolizumab (Keytruda) and nivolumab (Opdivo), and three anti-PD-L1 drugs: atezolizumab (Tecentriq), avelumab (Bavencio)… Read more »